A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression - PubMed (original) (raw)
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression
Janete M Cerutti et al. J Clin Invest. 2004 Apr.
Abstract
Accurate diagnosis of thyroid tumors is challenging. A particular problem is distinguishing between follicular thyroid carcinoma (FTC) and benign follicular thyroid adenoma (FTA), where histology of fine-needle aspirates is not conclusive. It is often necessary to remove healthy thyroid to rule out carcinoma. In order to find markers to improve diagnosis, we quantified gene transcript expression from FTC, FTA, and normal thyroid, revealing 73 differentially expressed transcripts (P < or = 0.0001). Using an independent set of 23 FTCs, FTAs, and matched normal thyroids, 17 genes with large expression differences were tested by real-time RT-PCR. Four genes (DDIT3, ARG2, ITM1, and C1orf24) differed between the two classes FTC and FTA, and a linear combination of expression levels distinguished FTC from FTA with an estimated predictive accuracy of 0.83. Furthermore, immunohistochemistry for DDIT3 and ARG2 showed consistent staining for carcinoma in an independent set 59 follicular tumors (estimated concordance, 0.76; 95% confidence interval, [0.59, 0.93]). A simple test based on a combination of these markers might improve preoperative diagnosis of thyroid nodules, allowing better treatment decisions and reducing long-term health costs.
Figures
Figure 1
Relative levels of expression determined by quantitative RT-PCR in 23 samples of FTA and FTC (black bars) and in normal thyroid tissues (gray bars). Transcript levels were normalized to the average of ribosomal protein 8 and t-complex 1, which were uniformly expressed in all three thyroid SAGE libraries. Numbers 1–10 correspond to FTA and 11–23 to FTC cases described in Table 2. The statistical analysis of RT-PCR values revealed that expression of the genes DDIT3, ARG2, and ITM1 was significantly different at the 0.05 level, and expression of C1orf24 was significant at the 0.10 level.
Figure 2
Quantitative RT-PCR products of three genes with statistically significant expression differences, showing adenoma (A), FTC (C), and normal thyroid (N) tissues and thyroid carcinoma cell lines (CL). The genes DDIT3, ARG2, and ITM1 are expressed in most of the FTCs, the thyroid follicular carcinoma cell line (CL1), the papillary thyroid carcinoma cell line (CL2), and the undifferentiated thyroid carcinoma cell line (CL3), but not in normal tissue and most FTAs. Case 6 (A6) expressed ARG2 and ITM1 and was misclassified according to our class-predicted genes. Universal Human Reference RNA (UHR) was used as a control. Ribosomal protein 8 was used as a calibrator gene. The 100-bp DNA ladder (M) is shown in the far left and far right lanes. The results are shown in triplicate, and the numbers correspond to cases analyzed (Table 2). The product sizes and PCR conditions are described in Methods and summarized in Supplemental Table 1. Negative control (NC) consists of PCR mix and primers, but no template.
Figure 3
Immunohistochemical analysis of DDIT3 (A–F) and ARG2 (G–L) in paraffin-embedded sections of FTAs and FTCs. FTCs exhibited strong brown immunostaining for DDIT3 (D–F) and ARG2 (J–L). In contrast, FTAs (A–C and G–I) exhibited no immunoreactivity. The arrows in D and F show the vascular invasion in FTCs and the follicular cells that are positive for DDIT3. The arrow in L shows the normal thyroid tissue that was negative for ARG2, adjacent to tumor area that was positive for ARG2. Hematoxylin was used as a nuclear counterstain. Original magnification, ×100 for A–E and G–L, ×40 for F.
Similar articles
- Diagnosis of suspicious thyroid nodules using four protein biomarkers.
Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J, Riggins GJ. Cerutti JM, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3311-8. doi: 10.1158/1078-0432.CCR-05-2226. Clin Cancer Res. 2006. PMID: 16740752 - The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors.
Sigstad E, Paus E, Bjøro T, Berner A, Grøholt KK, Jørgensen LH, Sobrinho-Simões M, Holm R, Warren DJ. Sigstad E, et al. Mod Pathol. 2012 Apr;25(4):537-47. doi: 10.1038/modpathol.2011.188. Epub 2011 Dec 9. Mod Pathol. 2012. PMID: 22157935 Free PMC article. - Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction.
Taniguchi K, Takano T, Miyauchi A, Koizumi K, Ito Y, Takamura Y, Ishitobi M, Miyoshi Y, Taguchi T, Tamaki Y, Kato K, Noguchi S. Taniguchi K, et al. Oncology. 2005;69(5):428-35. doi: 10.1159/000089998. Epub 2005 Nov 25. Oncology. 2005. PMID: 16319515 - [Nodule diagnosed as follicular patterned lesion: are biomarkers the promise?].
Cerutti JM. Cerutti JM. Arq Bras Endocrinol Metabol. 2007 Jul;51(5):832-42. doi: 10.1590/s0004-27302007000500022. Arq Bras Endocrinol Metabol. 2007. PMID: 17891248 Review. Portuguese. - Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Freitas BC, Cerutti JM. Freitas BC, et al. Mol Cell Endocrinol. 2010 May 28;321(1):77-85. doi: 10.1016/j.mce.2009.11.008. Epub 2009 Nov 20. Mol Cell Endocrinol. 2010. PMID: 19932149 Review.
Cited by
- Transcriptomic analysis reveals that NIBAN1 overexpression is associated with BRAFV600E mutation and increases the aggressiveness of thyroid cancer.
Diana P, Ribeiro Carneiro TN, Cerutti JM, Kuroshu RM, Carvalheira GMG. Diana P, et al. Genes Dis. 2023 Sep 14;11(4):101094. doi: 10.1016/j.gendis.2023.101094. eCollection 2024 Jul. Genes Dis. 2023. PMID: 38425426 Free PMC article. No abstract available. - Utility of the Growth Differentiation Factor-15 in the Differential Diagnosis of Follicular-Patterned Lesions of the Thyroid on Cytopathologic and Histopathologic Samples.
Perumal PV, Siddaraju N, Saxena SK, Rajendiran S, Bhat RV. Perumal PV, et al. Cureus. 2023 Sep 29;15(9):e46206. doi: 10.7759/cureus.46206. eCollection 2023 Sep. Cureus. 2023. PMID: 37905271 Free PMC article. - In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators.
Zaki MEA, Al-Hussain SA, Al-Mutairi AA, Samad A, Ghosh A, Chaudhari S, Khatale PN, Ajmire P, Jawarkar RD. Zaki MEA, et al. Front Pharmacol. 2023 Apr 18;14:1129997. doi: 10.3389/fphar.2023.1129997. eCollection 2023. Front Pharmacol. 2023. PMID: 37144217 Free PMC article. - Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer.
Kuo CY, Jhuang JY, Huang WC, Cheng SP. Kuo CY, et al. J Histochem Cytochem. 2022 Oct;70(10):707-716. doi: 10.1369/00221554221138370. Epub 2022 Nov 2. J Histochem Cytochem. 2022. PMID: 36321670 Free PMC article. - Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE, Lisle TL, Perez-Penco M, Schina A, Hübbe ML, Siersbæk M, Holmström MO, Jørgensen MA, Marie Svane I, Met Ö, Ødum N, Madsen DH, Donia M, Grøntved L, Andersen MH. Weis-Banke SE, et al. J Immunother Cancer. 2022 Oct;10(10):e005326. doi: 10.1136/jitc-2022-005326. J Immunother Cancer. 2022. PMID: 36316062 Free PMC article.
References
- Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin. Proc. 1994;69:44–49. - PubMed
- Mazzaferri EL. Management of a solitary thyroid nodule. N. Engl. J. Med. 1993;328:553–559. - PubMed
- Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987;31:587–590. - PubMed
- Inohara H, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer. 1999;85:2475–2484. - PubMed
- Bartolazzi A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644–1650. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous